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ABSTRACT
Introduction: Non-alcoholic fatty liver disease
(NAFLD), one of the most common liver dis-
eases, is associated with liver-related complica-
tions and metabolic comorbidities. The
phenotype is wide, ranging from simple
steatosis to non-alcoholic steatohepatitis with
advanced fibrosis. In this analysis of a phase 1
trial, clinical characteristics of screened subjects
with NAFLD were studied according to the
extent of fibrosis assessed using magnetic reso-
nance elastography (MRE).
Methods: One hundred ninety-four subjects
with body mass index (BMI) of 25–40 kg/m2 and
suspected NAFLD were assessed by MRE and
grouped by MRE thresholds as a proxy for
fibrosis staging (groups 0–4). Data were sum-
marized by group levels, and correlation analy-
ses between MRE values and clinical parameters
(including magnetic resonance imaging-proton
density fat fraction) were performed.
Results: Most subjects had MRE values in the
lower range (groups 0–1; N = 148). Type 2 dia-
betes (T2D) and BMI[35 kg/m2 were more
frequent in groups with higher than lower MRE
values. Subjects in the highest MRE groups also
tended to be older and have higher liver enzyme
concentrations compared with lower MRE
groups. No, or weak, correlations were found
between MRE values and clinical parameters (all
r values B 0.45).
Conclusions: There was considerable variation
and overlap in clinical characteristics across the
spectrum of liver stiffness. Although groups
with high MRE values generally included more
subjects with T2D and obesity, and had higher
age and concentrations of liver enzymes, the
clinical characteristics did not strongly correlate
with MRE scores in this population.
Trial Registration: Registered on Clinicaltri-
als.gov on November 29, 2017 (NCT03357380).
G. Andersen (&)





Antaros Medical, BioVenture Hub, 43183 Mölndal,
Sweden
P. D. Hockings
MedTech West, Chalmers University of Technology,
Gothenburg, Sweden
A. Morsing  O. Svolgaard
Medical and Science, Obesity and Metabolism,
Novo Nordisk A/S, Søborg, Denmark
M. S. Palle
Biostatistics, Global, Development, Novo Nordisk
A/S, Søborg, Denmark
A. Flint
Clinical Pharmacology and Translational Medicine,
Novo Nordisk A/S, Søborg, Denmark
Adv Ther
https://doi.org/10.1007/s12325-020-01503-x
Keywords: Fibrosis; Magnetic resonance
elastography; Non-alcoholic fatty liver disease
Key Summary Points
This study of subjects with non-alcoholic
fatty liver disease looked at the clinical
features of the subjects grouped according
to the extent of their disease (liver
stiffness).
Those with more advanced disease (greater
stiffness of the liver) more often also had
type 2 diabetes, obesity, liver enzyme
abnormalities, or were of older age.
However, there was no clear association or
correlation between the presence of liver
disease and the clinical features of
subjects.
DIGITAL FEATURES
This article is published with digital features,
including a summary slide, to facilitate under-
standing of the article. To view digital features
for this article go to https://doi.org/10.6084/
m9.figshare.12928817.
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) rep-
resents the most common cause of liver disease
and is estimated to affect approximately 25% of
the adult population globally [1]. Type 2 dia-
betes (T2D) and obesity are among the strongest
risk factors for NAFLD development, and as
their prevalence increases, that of NAFLD is also
expected to rise further [2]. NAFLD is classified
into non-alcoholic fatty liver, which is charac-
terized by simple hepatic steatosis, and the
more advanced subtype, non-alcoholic steato-
hepatitis (NASH), where steatosis is accompa-
nied by inflammation and ballooning [2].
Around one in four patients with NAFLD have
NASH, with the associated progressive hepatic
fibrosis, cirrhosis, and hepatocellular carcinoma
causing significant morbidity and mortality [3].
At present, lifestyle modification is the
cornerstone of treatment for patients with
NAFLD. Although many potential treatment
modalities are in development, including
glucagon-like peptide-1 receptor agonists
(GLP-1RAs) approved for the treatment of T2D
and obesity, no medical treatment options for
NASH are currently approved [4].
Another key issue in patients with NAFLD is
the differentiation of simple steatosis from
inflammation (i.e., NASH) and advanced hep-
atic fibrosis. The use of biopsy, recognized as the
gold standard, is limited by factors including its
invasive nature, sampling bias, and risk of
complications [5]. Magnetic resonance (MR)
elastography (MRE) can non-invasively deter-
mine liver stiffness, a surrogate marker for
assessing liver fibrosis, via analysis of shear
waves induced in the liver by low-frequency
vibrations applied to the abdominal wall [6, 7].
Indeed, MRE has been shown to predict fibrosis
in patients with NAFLD, with high diagnostic
accuracy [3, 6, 7]. In a pooled analysis of indi-
vidual participant-level data (n = 232), MRE was
able to discriminate any fibrosis (stage 1, area
under the receiver-operating curve [AUC] 0.86),
significant fibrosis (stage 2, AUC 0.87),
advanced fibrosis (stage 3, AUC 0.90), and cir-
rhosis (stage 4, AUC 0.91) [8].
A trial investigated the effect of semaglutide,
a GLP-1RA given by subcutaneous injection, on
liver fibrosis assessed by MRE and other
parameters in subjects with NAFLD. In the cur-
rent analysis, the clinical characteristics of
screened subjects from the trial were studied
across groups, based on the extent of fibrosis
assessed using MRE.
METHODS
This analysis was conducted as part of a ran-
domized, double-blind, placebo-controlled,
parallel-group, phase 1 trial that investigated
the effects of subcutaneous treatment with
semaglutide versus placebo on liver fibrosis as
assessed by MRE (ClinicalTrials.gov identifier,
NCT03357380). Effects on MR imaging-proton
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density fat fraction (MRI-PDFF) and other
aspects of NAFLD were also assessed. The trial
protocol was approved by relevant local inde-
pendent ethics committees (Neuss: Ethics
Committee, Medical Association of North
Rhine; Mainz: Ethics Committee, State Medical
Association of Rhineland-Palatinate; reference
2017273). This trial is being conducted in
accordance with the Declaration of Helsinki and
International Council for Harmonisation of
Technical Requirements for Pharmaceuticals for
Human Use. All subjects provided written
informed consent before any trial-related
activities were initiated.
The current analysis included all subjects with
evaluable MRE data in the screening population
of the phase 1 study, including subjects who did
not meet the eligibility criteria of the parent
study. Eligibility criteria for the phase 1 study
included: 18–75 years of age, body mass index
(BMI) 25–40 kg/m2, liver stiffness 2.50–4.63 kPa
(inclusive) measured by MRE, and liver steato-
sis C 10% measured by MRI-PDFF. Subjects with
or without T2D were eligible. Key exclusion cri-
teria included documented causes of chronic
liver disease other than NAFLD (including
NASH), known or suspected abuse of alcohol,
and glycated hemoglobin (HbA1c)[9.5%. MR
assessments were conducted using a Siemens
1.5T MR imaging (MRI) scanner. MRE scans were
acquired in four axial slices following 4 h of
fasting and in accordance with the Quantitative
Imaging Biomarkers Alliance guidelines [9].
Briefly, the passive driver was placed over the
right lower chest wall at the level of the xiphis-
ternum in the midclavicular line. Regions of
interest were drawn at least 1 cm inside the liver
boundary, avoiding areas of incoherent waves,
and contained a minimum of 500 pixels per slice.
Liver fat content was assessed using MRI-PDFF
over the entire liver.
The demographics and clinical characteristics
of the screened subjects were recorded and
blood samples collected. Alanine aminotrans-
ferase (ALT), aspartate aminotransferase (AST),
alkaline phosphatase (ALP), gamma-glutamyl
transferase (GGT), HbA1c, total bilirubin, high-
sensitivity C-reactive protein (hsCRP), and
international normalized ratios (INRs) were
measured. Fibrosis-4 score (FIB-4; based on
patient age, platelet count, AST, and ALT [10])
and NAFLD fibrosis score (NFS; based on patient
age, BMI, platelet count, AST to ALT ratio,
albumin, and the presence of diabetes/impaired
glucose tolerance [11]) were calculated. Kaya
et al. [12] have previously advised that FIB-4 and
NFS scores have an acceptable diagnostic per-
formance in the exclusion of advanced fibrosis
in patients with normal or elevated transami-
nases. FIB-4 scores of\1.3 and[ 2.67 indicate a
low and high risk for advanced fibrosis, respec-
tively [13, 14]; NFS\ –1.455 indicates that
advanced fibrosis is unlikely, but a score C 0.67
indicates a high probability of fibrosis [11].
To investigate possible patterns in the
demographics, body measurements, or other
clinical parameters across the MRE-based fibro-
sis spectrum, the subjects were categorized into
five groups (0–4), according to MRE thresholds
of\ 2.61, 2.61–2.96, 2.97–3.61, 3.62–4.69,
and C 4.70 kPa, respectively. Groupings were
based on data from the study by Hsu et al.,
where both MRE and corresponding confirma-
tory biopsies for fibrosis stage (F0–F4) were
available [15]. Geometric mean and coefficient
of variation were presented for subject charac-
teristics and clinical parameters, unless other-
wise specified. Comparison of MRE with other
biomarkers on a continuous scale, instead of
categorizing them, results in preservation of
more data information. Therefore, to assess any
possible correlation between MRE and age, BMI,
ALT, AST, GGT, NFS, FIB-4, MRI-PDFF, and
HbA1c (for subjects with and without T2D sep-
arately), data were plotted and a Spearman
correlation coefficient calculated.
RESULTS
A total of 194 subjects in the screening popu-
lation of the phase 1 trial had evaluable MRE
data and were thus included in this analysis.
Liver-related characteristics measured by MR
and grouped by liver stiffness are shown in
Table 1. There was a high number of subjects in
groups 0 and 1 (n = 82 and n = 66, respectively)
compared with groups 2–4 (n = 21, n = 14, and
n = 11, respectively). Mean values for liver
steatosis by MRI-PDFF generally increased
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slightly across MRE groups, from 11.9% in
group 0 to 14.2% in group 4.
The demographics and clinical parameters
by liver stiffness groups are shown in Table 2.
The majority of subjects (62.2–81.0%) in all
groups were male. The highest mean (standard
deviation) age and BMI were observed in
group 3 (63.0 [9.6] years and 34.6 [3.6] kg/m2,
respectively) and group 4 (61.8 [9.4] years and
34.5 [4.5] kg/m2, respectively). In line with this,
groups 3 and 4 had the greatest proportion of
subjects with BMI[35 kg/m2 compared with
groups 0–2 (42.9–54.5% in groups 3 and 4 vs.
25.8–35.4% in groups 0–2). The highest preva-
lence of T2D was also seen in subjects in
groups 3 and 4 ([ 90%) compared with groups
0–2 (\77%). ALT, AST, and GGT levels gener-
ally increased with liver stiffness from group
0–4, although groups 2 and 3 were similar.
Group 4 showed the highest geometric mean of
41.7 U/l, 39.0 U/l, and 86.8 U/l for ALT, AST,
and GGT levels, respectively. There was no
apparent trend across groups 0–4 for levels of
ALP, total bilirubin, hsCRP, INR, or systolic or
diastolic blood pressure.
Small differences were observed across the
groups for both FIB-4 and NFS, but mean values
for both parameters generally increased with
increasing MRE group. For FIB-4, the geometric
mean values ranged from 1.1 in group 0 to 1.9
in group 4, and 3.6% of subjects were catego-
rized as being at high risk of advanced fibrosis.
For NFS, mean values ranged from - 1.2 in
group 0 to 0.2 in group 4; 10.3% of subjects
were considered at high risk of advanced fibrosis
based on their NFS.
Scatter plots and the Spearman correlation
coefficient of clinical parameters and MRE val-
ues are shown in Fig. 1. The Spearman correla-
tion coefficient between MRE values and age
(r = 0.07), BMI (r = 0.07), ALT (r = 0.16), AST
(r = 0.20), NFS (r = 0.24), FIB-4 score (r = 0.18),
and MRI-PDFF (r = 0.07) showed no or very weak
correlations. Weak correlations were observed
between MRE values and HbA1c for subjects
without T2D (r = 0.45) and GGT (r = 0.34).
There was no correlation between HbA1c and
MRE values in subjects with T2D (r = 0.05).
DISCUSSION
The screened cohort with evaluable MRE data
presented a broad spectrum of NAFLD. Subjects
in all five MRE-based fibrosis groups (0–4) were
included, although most subjects (76%) had
low-level fibrosis (groups 0–1). We observed
that subjects with more advanced group 3 or 4
Table 1 Liver-related characteristics measured by magnetic resonance

























11.9 (87.9) 13.5 (69.4) 13.7 (87.3) 13.1 (77.2) 14.2 (100.6)
CV coefficient of variation, MRE magnetic resonance elastography, MRI-PDFF magnetic resonance imaging-proton density
fat fraction
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Table 2 Demographics and clinical parameters by liver stiffness measured by MRE
















Male, n (%) 51 (62) 46 (70) 17 (81) 10 (71) 7 (64)
Age group, years
C 18 to\ 65, n (%) 59 (72) 42 (64) 12 (57) 5 (36) 6 (55)
C 65 to\ 75, n (%) 23 (28) 24 (36) 9 (43) 9 (64) 5 (46)
Mean (SD) 59.0 (7.8) 60.1 (8.3) 60.0 (10.1) 63.0 (9.6) 61.8 (9.4)
BMI, kg/m2
C 25 to\ 30, n (%) 10 (12) 5 (8) 4 (19) 1 (7) 2 (18)
C 30 to\ 35, n (%) 43 (52) 44 (67) 10 (48) 7 (50) 3 (27)
C 35 to\ 40, n (%) 29 (35) 17 (26) 7 (33) 6 (43) 6 (55)
Mean (SD) 33.6 (3.4) 33.8 (2.7) 33.3 (3.4) 34.6 (3.6) 34.5 (4.5)
Type 2 diabetes
mellitus, n (%)




7.2 (0.9) 7.2 (1.1) 7.3 (0.8) 7.5 (1.1) 7.3 (1.1)
Non-type 2 diabetes,
mean (SD)




29.1 (50.5) 33.5 (54.9) 32.7 (56.8) 27.1 (54.3) 41.7 (44.6)
Aspartate aminotransferase, U/l












8.3 (45.6) 7.3 (46.2) 7.1 (58.4) 7.0 (47.7) 8.6 (37.6)
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fibrosis (13%) had a higher prevalence of T2D
and obesity and were older compared with
subjects in groups 0–2. Konerman et al. descri-
bed a risk stratification approach to identify and
differentiate subjects with high likelihood of
NASH and fibrosis for clinical trials and, con-
sistent with the current findings, listed
advanced age, T2D, and obesity as important
factors [4].
Genetically driven T2D and obesity have
both been shown to causally increase the risk of
NAFLD [16]. Advanced fibrosis (defined as
MRE C 3.6 kPa) is common in T2D, occurring in
7.1% of 100 patients in a cross-sectional study
[17]. T2D is a known independent predictor of
advanced fibrosis in NAFLD [18], and the
pathogenesis of diabetes and NAFLD is thought
to be related to insulin resistance and hyperin-
sulinemia [19, 20]. Studies have demonstrated a
more aggressive course of NAFLD in diabetes
and higher risk of cirrhosis in patients with T2D
and NAFLD [21, 22].
As the value of MRI for elastography and
PDFF determination is being increasingly
demonstrated [6–8, 23–26], it is being used
more widely in phase 1 and phase 2a studies to
assess dynamic changes in liver stiffness and
liver steatosis. MRI-PDFF has been shown to
correlate strongly with hepatic fat assessed his-
tologically in both adults and children [27, 28].
The correlation of MRI-PDFF with histologic
steatosis was found to be stronger for higher
fibrosis stages in children [28], and in the cur-
rent analysis, MRI-PDFF increased with
increasing liver stiffness.
In a meta-analysis to compare different
methods to detect fibrosis in patients with
NAFLD confirmed by biopsy, MRE and shear
Table 2 continued
















High-sensitivity C-reactive protein, mg/l
Geometric mean
(CV)




1.0 (6.0) 1.0 (7.0) 1.0 (6.1) 1.1 (7.4) 1.1 (6.5)
Systolic blood pressure, mmHg
Mean (SD) 137.6 (12.2) 136.8 (11.6) 140.6 (11.5) 137.0 (14.9) 139.9 (14.7)
Diastolic blood pressure, mmHg




1.1 (36.4) 1.3 (45.5) 1.2 (36.8) 1.3 (55.5) 1.9 (30.7)
NAFLD fibrosis score
Mean (SD) –1.2 (1.1) –0.7 (1.2) –1.0 (1.2) –0.4 (1.5) 0.2 (0.8)
BMI body mass index, CV coefficient of variation, HbA1c glycated hemoglobin, INR international normalized ratio,
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r = 0.20
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r = 0.24
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r = 0.07
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r = 0.34













3 4 5 6 7 8
T2D r = 0.05
Non-T2D r = 0.45
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wave elastography appeared to have the highest
diagnostic accuracy for staging fibrosis [29].
Furthermore, MRE was found to be more
accurate than ultrasound-based transient elas-
tography for the identification of liver fibrosis
(stage 1 or more) in a prospective cross-sectional
study of [ 100 patients with NAFLD where
biopsy analysis was the standard [30]. In the
current ongoing trial, the MRE thresholds for
each stage were the same as those proposed in a
systematic review and pooled analysis from
heterogenous populations [15]. Recently, in a
longitudinal study, a 15% increase in liver
stiffness on MRE was a predictor for an
increased likelihood of histologic fibrosis pro-
gression as well as progression from early to
advanced fibrosis [31]. Further validation of
clinically relevant MRE thresholds is needed to
enable MRE to be used more widely to diagnose
and monitor fibrosis and response to treatment.
In the current study in groups 3 and 4, geo-
metric mean FIB-4 was C 1.3, and mean NFS
was [ -0.4. Of the four laboratory non-inva-
sive tests studied in the meta-analysis by Xiao
et al. (NFS, FIB-4, aminotransferase to platelets
ratio index, and BARD score), the best diag-
nostic performance for detecting advanced
fibrosis was offered by NFS and FIB-4 [29];
however, it is known that they have limited
diagnostic accuracy for lesser stages of fibrosis
[31], which most subjects had in the present
study.
Subjects in the groups with the highest MRE
values were generally older and were more
likely to have obesity and T2D in the current
study, with no other distinct patterns observed
across the liver stiffness spectrum. The data set
showed considerable variability in clinical
characteristics across the groups, with a weak
upward trend observed between MRE-based
liver stiffness groups and mean values of NFS
and FIB-4 and between MRE and concentrations
of the liver enzymes, ALT, AST, and GGT. No or
very weak-to-weak correlations were seen
between MRE values and other clinical
characteristics.
A limitation of this analysis is the relatively
small number of subjects in groups 3 and 4.
Further studies with larger populations of
patients with advanced fibrosis would help to
confirm or refute any possible associations. In
addition, liver biopsy data were not available to
confirm the severity of fibrosis as this was
beyond the scope of the phase 1 study and
present analysis.
CONCLUSIONS
The present study showed a considerable varia-
tion and overlap in clinical characteristics
across groups of increasing liver stiffness as a
surrogate marker of liver fibrosis. In general,
groups with the highest MRE values included
subjects with greater prevalence of T2D and
obesity, with higher age and values of liver
enzymes, but the correlation analysis did not
reveal any strong associations. Further investi-
gations are warranted.
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